WWTR1 and cancer: This approach appears effective in preclinical experiments, with BRD repression via treatment with JQ1, a broad-acting BET inhibitor [247], and BRD2/3/4 KD showing anti-cancer potential in vivo models of YAP/TAZ-addicted breast cancer [164].